In New York on September 3, 2025, Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, announced they have finalized convertible note subscription agreements with SurgCenter principals and current Mesoblast shareholders, Gregory George and William Gueck. This agreement allows Mesoblast to potentially issue up to US$50.0 million (A$76.8 million) of unsecured convertible notes. The funding, subject to shareholder approval, can be used to repay or decrease the amount owed to secured lenders from existing loan agreements, as well as for general working capital needs.